Cel-Sci Corp (CVM) 0.63 $CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results
Business Wire - Tue Feb 09, 3:20PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2015.
CVM: 0.63 (+0.03)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.63 (+0.03), AMBX: (), CLDX: 8.19 (-0.06), ARQL: 1.72 (-0.06), CTIC: 0.59 (-0.01), CTMX: 13.66 (-0.09), ABBV: 56.15 (+0.22), XLRN: 28.47 (+0.50), ADXS: 8.64 (+0.97), AMGN: 145.98 (+0.14), BIND: 1.79 (-0.02), BMY: 64.71 (-0.29), BPTH: 1.59 (-0.26), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), CELGZ: 1.30 (-0.04)
Cervical Intraepithelial Neoplasia (CIN) Pipeline Review, H2 2015
M2 - Fri Feb 05, 7:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrmvx8/cervical) has announced the addition of the "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Intraepithelial Neoplasia (CIN), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cervical Intraepithelial Neoplasia (CIN) Overview - Therapeutics Development - Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview - Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis - Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies - Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes - Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies - Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes - Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development - CEL-SCI Corporation - Helix BioPharma Corp. - Inovio Pharmaceuticals, Inc. - PDS Biotechnology Corporation - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/hrmvx8/cervical
INO: 7.00 (-0.04), CVM: 0.63 (+0.03)
February Flaherty Financial Newsletter Features CEL-SCI Corporation's (NYSE MKT: CVM) Thrilling Phase III Cancer Immunotherapy Comeback and the Significance of the CEO's 3 Million Share Purchase
ACCESSWIRE - Thu Feb 04, 7:10AM CST
WEST HARRISON, NY / ACCESSWIRE / February 4, 2016 / A comeback management team has transformed CEL-SCI Corporation (NYSE MKT :CVM) into a classic special situation. That definition is a stock whose price should rise regardless of the overall stock market direction because of its intrinsic value and momentum.
CVM: 0.63 (+0.03)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.53 (+0.10), CVM: 0.63 (+0.03), CLDX: 8.19 (-0.06), IMGN: 8.27 (+0.08), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BIND: 1.79 (-0.02), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), ABBV: 56.15 (+0.22), XLRN: 28.47 (+0.50)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.63 (+0.03), GNCA: 4.31 (unch), GSK: 39.14 (-0.04), INO: 7.00 (-0.04), AZN: 28.87 (+0.13), IBIO: 0.55 (-0.01), CELGZ: 1.30 (-0.04)
CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 03, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.m. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York City.
CVM: 0.63 (+0.03)
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial
Business Wire - Mon Feb 01, 9:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"
today announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 697 as of January 31, 2016 in the world's largest Phase 3 study in head and neck cancer.
CVM: 0.63 (+0.03)
H5N1 Infection (Avian Influenza) Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6hqsb/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - H5N1 Infection (Avian Influenza) Overview - Therapeutics Development - Pipeline Products for H5N1 Infection (Avian Influenza) - Overview - Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis - H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies - H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes - H5N1 Infection (Avian Influenza) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - H5N1 Infection (Avian Influenza) - Products under Development by Companies - H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes - H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development - Akshaya Bio Inc. - Altimmune, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - BiondVax Pharmaceuticals Ltd. - CEL-SCI Corporation - Cocrystal Pharma, Inc. - CSL Limited - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - MedImmune, LLC - Microbiotix, Inc. - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - OPKO Health, Inc. - PaxVax, Inc. - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation For more information visit http://www.researchandmarkets.com/research/k6..._infection
BVXV: 3.68 (-0.01), CVM: 0.63 (+0.03), EBS: 35.41 (+0.57), NNVC: 2.51 (+0.06), GSK: 39.14 (-0.04), INO: 7.00 (-0.04), JNJ: 106.50 (-0.15), OPK: 9.70 (+0.10), NLNK: 18.18 (-0.36), IBIO: 0.55 (-0.01)
West Nile Virus Infections - Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/9frzff/west_nile_virus) has announced the addition of the "West Nile Virus Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - West Nile Virus Infections Overview - Therapeutics Development - Pipeline Products for West Nile Virus Infections - Overview - Pipeline Products for West Nile Virus Infections - Comparative Analysis - West Nile Virus Infections - Therapeutics under Development by Companies - West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes - West Nile Virus Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - West Nile Virus Infections - Products under Development by Companies - West Nile Virus Infections - Products under Investigation by Universities/Institutes - West Nile Virus Infections - Companies Involved in Therapeutics Development - BioDiem Ltd - CalAsia Pharmaceuticals, Inc. - CEL-SCI Corporation - Kineta, Inc. - Nanotherapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/9f...nile_virus
CVM: 0.63 (+0.03)
CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
Business Wire - Mon Jan 25, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.D., spoke to Newswise LIVE recently to discuss the following:
CVM: 0.63 (+0.03)
Cancer Immunotherapy - The Future of Cancer Treatment - What's Next in 2016 - Expert Dr. Eyal Talor, CEL-SCI Corporation
ACCESSWIRE - Thu Jan 21, 11:12AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." CEL-SCI Corporation (NYSE MKT: CVM), a Vienna-based biotech firm is now investigating their flagship investigational cancer immunotherapy called Multikine* (Leukocyte Interleukin, Injection), in a global Phase 3 clinical study what they believe is the logical next step in immunotherapy development. Based on the results of earlier human studies, researchers at CEL-SCI believe that immunotherapy should be administered as an initial therapy before a patient's immune system has been debilitated by surgery, radiation and chemotherapy.
CVM: 0.63 (+0.03)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 17.05 (-0.08), ABUS: 3.91 (+0.32), BSPM: 2.30 (+0.17), CMRX: 5.17 (+0.01), CVM: 0.63 (+0.03), ARWR: 4.33 (+0.09), ASMB: 5.91 (+0.58)
CEL-SCI Corporation to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
Business Wire - Thu Jan 14, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM), a Phase 3 cancer immunotherapy company, today announced that its Chief Executive Officer, Geert Kersten, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 3:00 p.m. Eastern Standard Time.
CVM: 0.63 (+0.03)
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016
Business Wire - Fri Jan 08, 6:00AM CST
The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders:
CVM: 0.63 (+0.03)
CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%
Parijat Sen - Zacks Investment Research - Thu Jan 07, 7:15AM CST
CEL-SCI Corporation (CVM) shares rose over 6% in the last trading session.
CVM: 0.63 (+0.03), ARNA: 1.51 (-0.05)
CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
Business Wire - Tue Jan 05, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company" today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. In the month of December it enrolled 33 patients. Total patient enrollment for the trial is now 668 as of December 31, 2015 in the world's largest Phase 3 study in head and neck cancer.
CVM: 0.63 (+0.03)
CEL-SCI Corporation - Product Pipeline Review Market Information Management Report 2015 - Acute Market Reports
M2 - Tue Jan 05, 2:52AM CST
'CEL-SCI CORPORATION - Product Pipeline Review - 2015', provides an overview of the CEL-SCI CORPORATION's pharmaceutical research and development focus.
CVM: 0.63 (+0.03)
"CEL-SCI Corporation's (NYSE: CVM): The January Effect Plus a Positive 2016!" is Featured in Flaherty Financial Newsletter #53 as Patient Enrollment in its Global Phase III Trial Booms
ACCESSWIRE - Mon Jan 04, 7:20AM CST
WEST HARRISON, NY / ACCESSWIRE / January 4, 2016 / The January Effect is a rally stemming from an increase in buying following December tax selling as investors create tax losses especially in small and micro-cap stocks. Measuring from Dec. 31st through Jan. 31st the Jan. percentage gains in shares of CEL-SCI Corporation (NYSE MKT: CVM) were 23% in 2015, 80% in 2014, 4% in 2013 and 17% in 2012. The average gain of 31% suggests shares could do very well in the first month of 2016.
CVM: 0.63 (+0.03)
Chlamydia Infections Pipeline Review, H2 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Thu Dec 17, 3:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dz7mn/chlamydia) has announced the addition of the "Chlamydia Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Abera Bioscience AB - Adamis Pharmaceuticals Corporation - Big DNA Ltd. - CEL-SCI Corporation - Folia Biotech Inc. - Genocea Biosciences, Inc. - Merck & Co., Inc. - Osel Inc. - Prokarium Limited - QureTech Bio AB - Selecta Biosciences, Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/6dz7mn/chlamydia
CVM: 0.63 (+0.03), MRK: 52.08 (-0.02), ADMP: 5.77 (+0.04), GNCA: 4.31 (unch)
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results
Business Wire - Tue Feb 09, 3:20PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2015.
CVM: 0.63 (+0.03)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.63 (+0.03), AMBX: (), CLDX: 8.19 (-0.06), ARQL: 1.72 (-0.06), CTIC: 0.59 (-0.01), CTMX: 13.66 (-0.09), ABBV: 56.15 (+0.22), XLRN: 28.47 (+0.50), ADXS: 8.64 (+0.97), AMGN: 145.98 (+0.14), BIND: 1.79 (-0.02), BMY: 64.71 (-0.29), BPTH: 1.59 (-0.26), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), CELGZ: 1.30 (-0.04)
Cervical Intraepithelial Neoplasia (CIN) Pipeline Review, H2 2015
M2 - Fri Feb 05, 7:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrmvx8/cervical) has announced the addition of the "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Intraepithelial Neoplasia (CIN), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cervical Intraepithelial Neoplasia (CIN) Overview - Therapeutics Development - Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview - Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis - Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies - Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes - Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies - Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes - Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development - CEL-SCI Corporation - Helix BioPharma Corp. - Inovio Pharmaceuticals, Inc. - PDS Biotechnology Corporation - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/hrmvx8/cervical
INO: 7.00 (-0.04), CVM: 0.63 (+0.03)
February Flaherty Financial Newsletter Features CEL-SCI Corporation's (NYSE MKT: CVM) Thrilling Phase III Cancer Immunotherapy Comeback and the Significance of the CEO's 3 Million Share Purchase
ACCESSWIRE - Thu Feb 04, 7:10AM CST
WEST HARRISON, NY / ACCESSWIRE / February 4, 2016 / A comeback management team has transformed CEL-SCI Corporation (NYSE MKT :CVM) into a classic special situation. That definition is a stock whose price should rise regardless of the overall stock market direction because of its intrinsic value and momentum.
CVM: 0.63 (+0.03)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.53 (+0.10), CVM: 0.63 (+0.03), CLDX: 8.19 (-0.06), IMGN: 8.27 (+0.08), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BIND: 1.79 (-0.02), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), ABBV: 56.15 (+0.22), XLRN: 28.47 (+0.50)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.63 (+0.03), GNCA: 4.31 (unch), GSK: 39.14 (-0.04), INO: 7.00 (-0.04), AZN: 28.87 (+0.13), IBIO: 0.55 (-0.01), CELGZ: 1.30 (-0.04)
CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 03, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.m. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York City.
CVM: 0.63 (+0.03)
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial
Business Wire - Mon Feb 01, 9:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"
today announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 697 as of January 31, 2016 in the world's largest Phase 3 study in head and neck cancer. CVM: 0.63 (+0.03)
H5N1 Infection (Avian Influenza) Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6hqsb/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - H5N1 Infection (Avian Influenza) Overview - Therapeutics Development - Pipeline Products for H5N1 Infection (Avian Influenza) - Overview - Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis - H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies - H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes - H5N1 Infection (Avian Influenza) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - H5N1 Infection (Avian Influenza) - Products under Development by Companies - H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes - H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development - Akshaya Bio Inc. - Altimmune, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - BiondVax Pharmaceuticals Ltd. - CEL-SCI Corporation - Cocrystal Pharma, Inc. - CSL Limited - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - MedImmune, LLC - Microbiotix, Inc. - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - OPKO Health, Inc. - PaxVax, Inc. - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation For more information visit http://www.researchandmarkets.com/research/k6..._infection
BVXV: 3.68 (-0.01), CVM: 0.63 (+0.03), EBS: 35.41 (+0.57), NNVC: 2.51 (+0.06), GSK: 39.14 (-0.04), INO: 7.00 (-0.04), JNJ: 106.50 (-0.15), OPK: 9.70 (+0.10), NLNK: 18.18 (-0.36), IBIO: 0.55 (-0.01)
West Nile Virus Infections - Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/9frzff/west_nile_virus) has announced the addition of the "West Nile Virus Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - West Nile Virus Infections Overview - Therapeutics Development - Pipeline Products for West Nile Virus Infections - Overview - Pipeline Products for West Nile Virus Infections - Comparative Analysis - West Nile Virus Infections - Therapeutics under Development by Companies - West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes - West Nile Virus Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - West Nile Virus Infections - Products under Development by Companies - West Nile Virus Infections - Products under Investigation by Universities/Institutes - West Nile Virus Infections - Companies Involved in Therapeutics Development - BioDiem Ltd - CalAsia Pharmaceuticals, Inc. - CEL-SCI Corporation - Kineta, Inc. - Nanotherapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/9f...nile_virus
CVM: 0.63 (+0.03)
CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
Business Wire - Mon Jan 25, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.D., spoke to Newswise LIVE recently to discuss the following:
CVM: 0.63 (+0.03)
Cancer Immunotherapy - The Future of Cancer Treatment - What's Next in 2016 - Expert Dr. Eyal Talor, CEL-SCI Corporation
ACCESSWIRE - Thu Jan 21, 11:12AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." CEL-SCI Corporation (NYSE MKT: CVM), a Vienna-based biotech firm is now investigating their flagship investigational cancer immunotherapy called Multikine* (Leukocyte Interleukin, Injection), in a global Phase 3 clinical study what they believe is the logical next step in immunotherapy development. Based on the results of earlier human studies, researchers at CEL-SCI believe that immunotherapy should be administered as an initial therapy before a patient's immune system has been debilitated by surgery, radiation and chemotherapy.
CVM: 0.63 (+0.03)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 17.05 (-0.08), ABUS: 3.91 (+0.32), BSPM: 2.30 (+0.17), CMRX: 5.17 (+0.01), CVM: 0.63 (+0.03), ARWR: 4.33 (+0.09), ASMB: 5.91 (+0.58)
CEL-SCI Corporation to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
Business Wire - Thu Jan 14, 8:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM), a Phase 3 cancer immunotherapy company, today announced that its Chief Executive Officer, Geert Kersten, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 3:00 p.m. Eastern Standard Time.
CVM: 0.63 (+0.03)
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016
Business Wire - Fri Jan 08, 6:00AM CST
The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders:
CVM: 0.63 (+0.03)
CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%
Parijat Sen - Zacks Investment Research - Thu Jan 07, 7:15AM CST
CEL-SCI Corporation (CVM) shares rose over 6% in the last trading session.
CVM: 0.63 (+0.03), ARNA: 1.51 (-0.05)
CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
Business Wire - Tue Jan 05, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"
today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. In the month of December it enrolled 33 patients. Total patient enrollment for the trial is now 668 as of December 31, 2015 in the world's largest Phase 3 study in head and neck cancer. CVM: 0.63 (+0.03)
CEL-SCI Corporation - Product Pipeline Review Market Information Management Report 2015 - Acute Market Reports
M2 - Tue Jan 05, 2:52AM CST
'CEL-SCI CORPORATION - Product Pipeline Review - 2015', provides an overview of the CEL-SCI CORPORATION's pharmaceutical research and development focus.
CVM: 0.63 (+0.03)
"CEL-SCI Corporation's (NYSE: CVM): The January Effect Plus a Positive 2016!" is Featured in Flaherty Financial Newsletter #53 as Patient Enrollment in its Global Phase III Trial Booms
ACCESSWIRE - Mon Jan 04, 7:20AM CST
WEST HARRISON, NY / ACCESSWIRE / January 4, 2016 / The January Effect is a rally stemming from an increase in buying following December tax selling as investors create tax losses especially in small and micro-cap stocks. Measuring from Dec. 31st through Jan. 31st the Jan. percentage gains in shares of CEL-SCI Corporation (NYSE MKT: CVM) were 23% in 2015, 80% in 2014, 4% in 2013 and 17% in 2012. The average gain of 31% suggests shares could do very well in the first month of 2016.
CVM: 0.63 (+0.03)
Chlamydia Infections Pipeline Review, H2 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Thu Dec 17, 3:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dz7mn/chlamydia) has announced the addition of the "Chlamydia Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Abera Bioscience AB - Adamis Pharmaceuticals Corporation - Big DNA Ltd. - CEL-SCI Corporation - Folia Biotech Inc. - Genocea Biosciences, Inc. - Merck & Co., Inc. - Osel Inc. - Prokarium Limited - QureTech Bio AB - Selecta Biosciences, Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/6dz7mn/chlamydia
CVM: 0.63 (+0.03), MRK: 52.08 (-0.02), ADMP: 5.77 (+0.04), GNCA: 4.31 (unch)
